Precedent Wealth Partners’s AbbVie ABBV Stock Holding History

Precedent Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.08M	Buy	16,214 +3,940	+32%	+$848K	0.68%	46
2026 Q1	$2.67M	Buy	12,274 +80	+0.7%	+$17.7K	0.53%	59
2025 Q4	$2.79M	Buy	12,194 +442	+4%	+$101K	0.58%	54
2025 Q3	$2.72M	Buy	11,752 +159	+1%	+$32.4K	0.6%	50
2025 Q2	$2.15M	Buy	11,593 +1,149	+11%	+$214K	0.53%	56
2025 Q1	$2.19M	Buy	10,444 +1,222	+13%	+$238K	0.61%	49
2024 Q4	$1.64M	Buy	9,222 +383	+4%	+$70.4K	0.53%	47
2024 Q3	$1.75M	Buy	8,839 +965	+12%	+$180K	0.58%	38
2024 Q2	$1.35M	Buy	7,874 +408	+5%	+$67.6K	0.54%	44
2024 Q1	$1.36M	Buy	7,466 +521	+8%	+$89.8K	0.58%	39
2023 Q4	$1.08M	Buy	+6,945	New	+$1.01M	0.55%	40

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Precedent Wealth Partners's ABBV Position: Q2 2026 in Review

Precedent Wealth Partners increased its AbbVie (ABBV) stake by 32% in Q2 2026, buying an estimated $848K and bringing the position to 16,214 shares worth $4.08M. The position accounts for 0.68% of the portfolio, ranked #46.

Precedent Wealth Partners first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Precedent Wealth Partners held 16,214 shares of AbbVie worth $4.08M as of Q2 2026.
Precedent Wealth Partners bought 3,940 AbbVie shares in Q2 2026, an estimated $848K.
AbbVie made up 0.68% of Precedent Wealth Partners's portfolio in Q2 2026, its #46 holding.
Precedent Wealth Partners first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Precedent Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.